PFE - Pfizer's Aggressive Stance In Obesity Drugs: CEO Albert Bourla Confirms Bold Bet Despite Prior Drug Hurdles | Benzinga
Monday, at the JP Morgan Healthcare Conference, Pfizer Inc (NYSE: PFE) CEO Albert Bourla expressed that the company is determined to move forward in the burgeoning obesity market despite setbacks involving a terminated weight-loss drug candidate due to severe side effects.
Major players like Eli Lilly And Co (NYSE: LLY) with Zepbound and Mounjaro and Novo Nordisk A/S's (NASDAQ: NVO) Wegovy already contribute significantly to this market.
These drugs, falling under the GLP-1 agonists category initially developed for type 2 diabetes, have displayed substantial revenue-generating capabilities. Novo's Ozempic, repurposed off-label for weight loss, is an example.
Citing ...